Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.
Yildirim ME, Karadurmuş N, Ökten İN, Türk HM, Urakçı Z, Arslan Ç, Çelik S, Dane F, Şendur MAN, Bilir C, Karabulut B, Cicin İ, Çubukçu E, Karaca M, Ozcelik M, Artaç M, Tanrikulu E, Alacacioglu A, Açıkgöz Ö, Öven B, Geredeli Ç, Çil T, Harputluoğlu H, Kefeli U, Bozkurt O, Tural D, Sakin A, Yalçın Ş, Gumus M. Yildirim ME, et al. Among authors: dane f. J Oncol Pharm Pract. 2024 Apr 13:10781552241241004. doi: 10.1177/10781552241241004. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 38613329
Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study.
Koca S, Beşiroğlu M, Özçelik M, Karaca M, Bilici M, Hacıoğlu B, Doğu GG, Kaplan NB, Oruç Z, Aydın D, Dane F. Koca S, et al. Among authors: dane f. J Oncol Pharm Pract. 2021 Apr;27(3):541-546. doi: 10.1177/1078155220924075. Epub 2020 May 16. J Oncol Pharm Pract. 2021. PMID: 32419618
Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.
Benekli M, Gumus M, Ozkan M, Dane F, Elkiran ET, Cicin I, Sevinc A, Aliustaoglu M, Isikdogan A, Meydan N, Oksuzoglu B, Ozyilkan O, Artac M, Ozdemir F, Kilickap S. Benekli M, et al. Among authors: dane f. J Oncol Pharm Pract. 2021 Oct;27(7):1623-1630. doi: 10.1177/1078155220963535. Epub 2020 Oct 13. J Oncol Pharm Pract. 2021. PMID: 33050804
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
Kefeli U, Benekli M, Sevinc A, Yildiz R, Kaplan MA, Ciltas A, Balakan O, Isikdogan A, Coskun U, Dane F, Harputluoglu H, Karaca H, Yazilitas D, Durnali A, Kaya AO, Demirci U, Gumus M, Buyukberber S. Kefeli U, et al. Among authors: dane f. Oncol Lett. 2013 Aug;6(2):605-611. doi: 10.3892/ol.2013.1408. Epub 2013 Jun 17. Oncol Lett. 2013. PMID: 24137379 Free PMC article.
The efficacy and reliability of sequential adjuvant anthracycline-based chemotherapy and weekly paclitaxel regimen in human epidermal growth factor receptor 2 negative breast cancer: A retrospective analysis of a multicentre study.
Ali Kaplan M, Oruc Z, Gumus M, Ozaydın S, Elkiran ET, Dinc NS, Sakin A, Berk V, Akman T, Aytekin A, Yazilitas D, Dane F, Imamoglu GI, Cubukcu E, Isikdogan A. Ali Kaplan M, et al. Among authors: dane f. J BUON. 2019 May-Jun;24(3):1081-1086. J BUON. 2019. PMID: 31424664 Free article.
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Yildiz R, Kalender ME, Dane F, Sevinc A, Gumus M, Camci C, Alici S, Kaya AO, Yaman E, Ozturk B, Coskun U, Benekli M, Uncu D, Buyukberber S. Yildiz R, et al. Among authors: dane f. J Oncol Pharm Pract. 2010 Sep;16(3):173-8. doi: 10.1177/1078155209347402. Epub 2009 Oct 15. J Oncol Pharm Pract. 2010. PMID: 19833685
Clinicopathologic and Prognostic Differences between Three Different Age Groups (Child/Adolescent, Young Adults, and Adults) of Colorectal Cancer Patients: A Multicentre Study.
Kaplan MA, Ozaydin S, Yerlikaya H, Karaagac M, Gumus M, Cil T, Yalcintas Arslan Ü, Ozdemir N, Sakin A, Bilici M, Koca D, Uysal M, Dane F, Sever ÖN, Seker MM, Oruc Seker Z, Can MF, Geredeli C, Aksoy A, Pilanci KN, Ozturk Topcu T, Isikdogan A. Kaplan MA, et al. Among authors: dane f. Oncol Res Treat. 2019;42(10):516-522. doi: 10.1159/000502120. Epub 2019 Aug 22. Oncol Res Treat. 2019. PMID: 31437835
205 results